Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
1.000
-0.010 (-0.99%)
At close: Jul 19, 2024, 4:00 PM
1.010
+0.010 (1.00%)
Pre-market: Jul 22, 2024, 9:06 AM EDT
Lineage Cell Therapeutics Employees
As of December 31, 2023, Lineage Cell Therapeutics had 75 total employees, including 68 full-time and 7 part-time employees. The number of employees decreased by 3 or -3.85% compared to the previous year.
Employees
75
Change (1Y)
-3
Growth (1Y)
-3.85%
Revenue / Employee
$106,707
Profits / Employee
-$315,413
Market Cap
188.82M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EDAP TMS | 307 |
Coherus BioSciences | 306 |
908 Devices | 230 |
Generation Bio Co. | 174 |
Inhibrx | 172 |
ClearPoint Neuro | 107 |
G1 Therapeutics | 100 |
Fractyl Health | 94 |
LCTX News
- 20 days ago - Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index - Business Wire
- 7 weeks ago - Lineage to Present at 2024 BIO International Convention - Business Wire
- 2 months ago - Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium - Business Wire
- 2 months ago - Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 - Business Wire
- 2 months ago - Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) - Business Wire
- 2 months ago - Lineage Announces Changes to Board of Directors - Business Wire